Raymond James Financial’s Arcutis Biotherapeutics ARQT Stock Holding History

Raymond James Financial’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.14M	Sell	43,474 -106,393	-71%	-$2.48M	﹤0.01%	3902
2026 Q1	$3.53M	Buy	149,867 +4,918	+3%	+$126K	﹤0.01%	2886
2025 Q4	$4.21M	Buy	144,949 +84,875	+141%	+$2.17M	﹤0.01%	2658
2025 Q3	$1.13M	Buy	60,074 +6,451	+12%	+$102K	﹤0.01%	3600
2025 Q2	$752K	Sell	53,623 -4,423	-8%	-$62K	﹤0.01%	3754
2025 Q1	$908K	Buy	+58,046	New	+$818K	﹤0.01%	3567

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Raymond James Financial's ARQT Position: Q2 2026 in Review

Raymond James Financial reduced its Arcutis Biotherapeutics (ARQT) stake by 71% in Q2 2026, selling an estimated $2.48M and leaving 43,474 shares worth $1.14M. The position accounts for ﹤0.01% of the portfolio, ranked #3902.

Raymond James Financial first reported a position in ARQT in Q1 2025 and has held it in 6 quarters since. The position peaked at $4.21M in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

Raymond James Financial held 43,474 shares of Arcutis Biotherapeutics worth $1.14M as of Q2 2026.
Raymond James Financial sold 106,393 Arcutis Biotherapeutics shares in Q2 2026, an estimated $2.48M.
Arcutis Biotherapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #3902 holding.
Raymond James Financial first reported a position in Arcutis Biotherapeutics in Q1 2025 and has held it in 6 quarters since.
Raymond James Financial's Arcutis Biotherapeutics position peaked at $4.21M in Q4 2025.
272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.